The Russell family of U.S. indexes is designed to be a comprehensive representation of the investable U.S. equity market and is reconstituted annually. The Russell 3000 Index measures the performance of the largest 3000 U.S. companies representing approximately 98 percent of the investable U.S. equity market. Membership in the Russell 3000 Index results in automatic inclusion in either the large-cap Russell 1000(R) Index or the widely used small-cap Russell 2000. The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity universe and includes approximately 2000 of the smallest securities based on a combination of their market cap and current index membership.
Russell indexes are widely used by managers for index funds and as benchmarks for both passive and active investment strategies. $4 trillion in assets currently are benchmarked to Russell indexes, and investment managers who oversee these funds purchase shares of member stocks according to that company's weighting in the particular index.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new medicines for cancer indications. In expanding its drug development efforts in the field of cancer through its targeted cancer drug development platform, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.
SOURCE: Curis, Inc.
Curis, Inc. Michael P. Gray, 617-503-6632 Chief Financial and Chief Operating Officer mgray@curis.com

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index